Background: Cancers are complex diseases rated among the top 10 causes of death worldwide. The Laboratory of Inflammatory and Neoplastic Cells at the
Both complexes turned to be promising compounds to use as adjuvant therapy for a selected cancer patient. As a private physician, over the last ten years, many cancer patients have been reached our clinic looking forward homeopathic medicines that could be used as a complimentary therapy to their standard cancer treatment. The types of cancer, as well as the stages of the disease, among those patients, were quite heterogeneous. We have followed not only those who have detected
Aims: To exchange observations and outcomes in the disease’s natural history of cancer patients who have been treated with M1 and M8 as adjuvant therapy to the standards treatments.
Methodology: The prescription of the treatment was based on primary
Results and discussion: Many cancer patients who were undergoing chemotherapy reported the side effects of that treatment had become mild in comparison to the time they were not using the complexes.
Conclusion: Although M1 and M8 act as biological response modifiers and their use as adjuvant therapy for cancer patients is a promising approach, the fact that cancer is a complex disease, which requires multiple approaches, brings an ethical consideration on the use or not use complementary therapies as adjuvant treatments. Our private practice showed up in the last decade that cancer patients can benefit from the use of those highly diluted complexes, adjuvant to standard treatments as chemotherapy and surgery.
Raffaello Popa Di Bernardi, Carolina Camargo de Oliveira, Dorly de Freitas Buchi.
International Journal of High Dilution Research – ISSN 1982-6206